Drug Trial Radar · NCT07551804
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 10, 2026
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.
Conditions
- Adult Growth Hormone Deficiency
Interventions
Inpegsomatropin InjectionDrug
Inpegsomatropin Injection,initial dose1mg/0.25ml, s.c. ,once a week
Placebo for Inpegsomatropin InjectionDrug
Placebo for Inpegsomatropin Injection,initial dose0.25ml, s.c. ,once a week
Inpegsomatropin InjectionDrug
Inpegsomatropin Injection,initial dose 2mg/0.5ml, s.c. ,once a week
Placebo for Inpegsomatropin InjectionDrug
Placebo for Inpegsomatropin Injection,initial dose 0.5ml, s.c. ,once a week
Inpegsomatropin InjectionDrug
Inpegsomatropin Injection,initial dose 4mg/1ml, s.c. ,once a week
Placebo for Inpegsomatropin InjectionDrug
Placebo for Inpegsomatropin Injection,initial dose 1.0ml, s.c. ,once a wee
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- Serious Adverse EventTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- Number of Participants with Abnormal Laboratory Parameters FindingsTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- HR (bpm)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- PR (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- QRS (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- QT (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- QTc (ms)Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- Number of participants with clinically significant changes in imaging examinationsTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- body weightTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- body Mass IndexTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- body temperatureTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- pulseTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- blood pressureTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- RespirationTime frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37
- Trunk fat percentageTime frame: Week 25
- Trunk fat massTime frame: Week 25
- Total fat massTime frame: Week 25
- Visceral adipose tissue (VAT)Time frame: Week 25
- Lean body mass (LBM)Time frame: Week 25
- Bone mineral density (BMD)Time frame: Week 25
- Quality of life score (QoL score)Time frame: Week 25
- BMITime frame: Week1Day1,Week25Day1
- Change from baseline in waist-to-hip ratioTime frame: Week3Day1,Week25Day1
- IGF-I /IGFBP-3Time frame: Week1Day1,Week25Day1
- CmaxTime frame: Week1Day1,Week25Day1
- CminTime frame: Week1Day1,Week25Day1
- TmaxTime frame: Week1Day1,Week25Day1
- AUC0-tTime frame: Week1Day1,Week25Day1
- AUC0-∞Time frame: Week1Day1,Week25Day1
- AUC0-tauTime frame: Week1Day1,Week25Day1
- Rac_CmaxTime frame: Week1Day1,Week25Day1
- Rac_AUC0-tauTime frame: Week1Day1,Week25Day1
- CL/FTime frame: Week1Day1,Week25Day1
- Vz/FTime frame: Week1Day1,Week25Day1
- DFTime frame: Week1Day1,Week25Day1
- t1/2Time frame: Week1Day1,Week25Day1
- ADATime frame: Week1Day1,Week29Day1
- NAbTime frame: Week1Day1,Week29Day1
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Henan, China · Recruiting
Huashan Hospital, Fudan University
Shanghai, China · Recruiting
West China Hospital, Sichuan University
Sichuan, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine
Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.